Log in to search using one of your social media accounts:


Forty Seven Inc. Receives $5 Million Grant from The California Institute for Regenerative Medicine (CIRM) to Support Ongoing Clinical Trial in Acute Myeloid Leukemia

CIRM grant will support further development of Forty Seven Inc.'s CD47 antibody Hu5F9-G4 in an ongoing second trial for the treatment of Acute Myeloid Leukemia and Myelodysplastic Syndrome MENLO PARK, Calif., Dec. 6, 2017 -- (Healthcare Sales &Marketin... Biopharmaceuticals, Regenerative Medicine, Oncology Forty Seven, acute myeloid leukemia, Myelodysplastic Syndrome, stem cell
Source: HSMN NewsFeed - Category: Pharmaceuticals Source Type: news

Related Links:

More News: Acute Leukemia | Acute Myeloid Leukemia | Cancer & Oncology | Clinical Trials | Grants | Leukemia | Men | Myelodysplastic Syndrome | Pharmaceuticals | Stem Cell Therapy | Stem Cells